ARCHIVES

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

This article is from The Cancer Letter archive.

Vol. 24 No. 16 | April 24, 1998

Download PDF Visit The Full Archive

Related Articles

Shubik Subcommittee Criticizes New Study Section, Asks NCI To Hire More Epidemiologists

December 5, 1975

Family History of BRCA Mutation Does Not Equal Increased Risk

October 28, 2011

Healy Comes To Defense Of NCI’s Robert Wittes; Official Has Been Target Of Innuendo Over Taxo

September 11, 1992

Walter Curran Succeeds Brian Leyland-Jones As Director Of Emory’s Cancer Center

September 25, 2009

Evidence Too Weak to Link Agent Orange, Cancer, IOM Says

March 22, 2002

Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable

April 26, 2013